Aug 28, 2024 FTC Submits Comment Supporting Proposed FDA Guidance on Interchangeable Biosimilar Drugs By Wil Holtz Biologic treatments for medical conditions are becoming increasingly prevalent. According to the Food and Drug Administration (FDA), they...
Mar 20, 2024 USTPO Issues Means-Plus-Function Memorandum By Wil Holtz On March 18, 2024, the United States Patent and Trademark Office (USPTO) issued a memorandum to the Patent Examining Corps regarding the...
Jan 10, 2024 USPTO Says Wands is Still the Test Post-Amgen By Wil Holtz The United States Patent and Trademark Office issued a notice in the Federal Register on January 10, 2024, providing guidelines to assist...
Dec 11, 2023 Biden-Harris administration announces actions to lower health care costs by promoting competition By Wil Holtz The high cost of prescription drugs is a concern for many. While most may agree that lowering these prices is a worthy goal, just how to...
Nov 30, 2023 Patent Term Adjustment woes By Wil Holtz Generally, receiving Patent Term Adjustment (PTA) for a patent that took the United States Patent Office (USPTO) a long time to issue is...
Nov 08, 2023 The USPTO's ESF-Web and Private PAIR systems will live to see another week By Wil Holtz The United States Patent and Trademark Office (USPTO) announced at the last moment that it will postpone decommissioning the legacy...
Nov 03, 2023 InvestMidwest 2024 applications open By Wil Holtz The application process is now open for presenting at InvestMidwest in April 2024 in Kansas City. This is an exciting opportunity for...
Oct 25, 2023 USPTO report on COVID-19 diagnostic patent applications By Wil Holtz Most of us have undergone some type of COVID-19 testing. This report on the origin and funding of COVID-19 diagnostic patent applications...